Cargando…

Real-Life Performance of F-18-FDG PET/CT in Patients with Cervical Lymph Node Metastasis of Unknown Primary Tumor

Background: Neoplasms in the head and neck region possess higher glycolytic activity than normal tissue, showing increased glucose metabolism. F-18-Flourodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) can identify an unknown primary tumor (CUP). Aim: The aim of this stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Eilsberger, Friederike, Noltenius, Friederike Elisabeth, Librizzi, Damiano, Wessendorf, Joel, Luster, Markus, Hoch, Stephan, Pfestroff, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495705/
https://www.ncbi.nlm.nih.gov/pubmed/36140197
http://dx.doi.org/10.3390/biomedicines10092095
_version_ 1784794084902174720
author Eilsberger, Friederike
Noltenius, Friederike Elisabeth
Librizzi, Damiano
Wessendorf, Joel
Luster, Markus
Hoch, Stephan
Pfestroff, Andreas
author_facet Eilsberger, Friederike
Noltenius, Friederike Elisabeth
Librizzi, Damiano
Wessendorf, Joel
Luster, Markus
Hoch, Stephan
Pfestroff, Andreas
author_sort Eilsberger, Friederike
collection PubMed
description Background: Neoplasms in the head and neck region possess higher glycolytic activity than normal tissue, showing increased glucose metabolism. F-18-Flourodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) can identify an unknown primary tumor (CUP). Aim: The aim of this study was to assess the real-life performance of F-18-FDG-PET/CT in detecting primary sites in patients with cervical lymph node metastasis of CUP. Methods: A retrospective data analysis of 31 patients who received FDG-PET/CT between June 2009 and March 2015 in a CUP context with histologically confirmed cervical lymph node metastasis was included. Results: In 48% of the patients (15/31), PET/CT showed suspicious tracer accumulation. In 52% of the patients (16/31), there was no suspicious radiotracer uptake, which was confirmed by the lack of identification of any primary tumor in 10 cases until the end of follow-up. FDG-PET/CT had a sensitivity of 67%, specificity of 91%, PPV of 92%, and NPV of 63% in detecting the primary tumor. Additionally, PET/CT showed suspicious tracer accumulation according to further metastasis in 32% of the patients (10/31). Conclusion: FDG-PET/CT imaging is a useful technique for primary tumor detection in patients in a cervical CUP context. Furthermore, it provides information on the ulterior metastasis of the disease.
format Online
Article
Text
id pubmed-9495705
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94957052022-09-23 Real-Life Performance of F-18-FDG PET/CT in Patients with Cervical Lymph Node Metastasis of Unknown Primary Tumor Eilsberger, Friederike Noltenius, Friederike Elisabeth Librizzi, Damiano Wessendorf, Joel Luster, Markus Hoch, Stephan Pfestroff, Andreas Biomedicines Article Background: Neoplasms in the head and neck region possess higher glycolytic activity than normal tissue, showing increased glucose metabolism. F-18-Flourodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) can identify an unknown primary tumor (CUP). Aim: The aim of this study was to assess the real-life performance of F-18-FDG-PET/CT in detecting primary sites in patients with cervical lymph node metastasis of CUP. Methods: A retrospective data analysis of 31 patients who received FDG-PET/CT between June 2009 and March 2015 in a CUP context with histologically confirmed cervical lymph node metastasis was included. Results: In 48% of the patients (15/31), PET/CT showed suspicious tracer accumulation. In 52% of the patients (16/31), there was no suspicious radiotracer uptake, which was confirmed by the lack of identification of any primary tumor in 10 cases until the end of follow-up. FDG-PET/CT had a sensitivity of 67%, specificity of 91%, PPV of 92%, and NPV of 63% in detecting the primary tumor. Additionally, PET/CT showed suspicious tracer accumulation according to further metastasis in 32% of the patients (10/31). Conclusion: FDG-PET/CT imaging is a useful technique for primary tumor detection in patients in a cervical CUP context. Furthermore, it provides information on the ulterior metastasis of the disease. MDPI 2022-08-27 /pmc/articles/PMC9495705/ /pubmed/36140197 http://dx.doi.org/10.3390/biomedicines10092095 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Eilsberger, Friederike
Noltenius, Friederike Elisabeth
Librizzi, Damiano
Wessendorf, Joel
Luster, Markus
Hoch, Stephan
Pfestroff, Andreas
Real-Life Performance of F-18-FDG PET/CT in Patients with Cervical Lymph Node Metastasis of Unknown Primary Tumor
title Real-Life Performance of F-18-FDG PET/CT in Patients with Cervical Lymph Node Metastasis of Unknown Primary Tumor
title_full Real-Life Performance of F-18-FDG PET/CT in Patients with Cervical Lymph Node Metastasis of Unknown Primary Tumor
title_fullStr Real-Life Performance of F-18-FDG PET/CT in Patients with Cervical Lymph Node Metastasis of Unknown Primary Tumor
title_full_unstemmed Real-Life Performance of F-18-FDG PET/CT in Patients with Cervical Lymph Node Metastasis of Unknown Primary Tumor
title_short Real-Life Performance of F-18-FDG PET/CT in Patients with Cervical Lymph Node Metastasis of Unknown Primary Tumor
title_sort real-life performance of f-18-fdg pet/ct in patients with cervical lymph node metastasis of unknown primary tumor
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495705/
https://www.ncbi.nlm.nih.gov/pubmed/36140197
http://dx.doi.org/10.3390/biomedicines10092095
work_keys_str_mv AT eilsbergerfriederike reallifeperformanceoff18fdgpetctinpatientswithcervicallymphnodemetastasisofunknownprimarytumor
AT nolteniusfriederikeelisabeth reallifeperformanceoff18fdgpetctinpatientswithcervicallymphnodemetastasisofunknownprimarytumor
AT librizzidamiano reallifeperformanceoff18fdgpetctinpatientswithcervicallymphnodemetastasisofunknownprimarytumor
AT wessendorfjoel reallifeperformanceoff18fdgpetctinpatientswithcervicallymphnodemetastasisofunknownprimarytumor
AT lustermarkus reallifeperformanceoff18fdgpetctinpatientswithcervicallymphnodemetastasisofunknownprimarytumor
AT hochstephan reallifeperformanceoff18fdgpetctinpatientswithcervicallymphnodemetastasisofunknownprimarytumor
AT pfestroffandreas reallifeperformanceoff18fdgpetctinpatientswithcervicallymphnodemetastasisofunknownprimarytumor